WP
STRO icon

Woodline Partners’s Sutro Biopharma STRO Stock Holding History

Woodline Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.2M Buy
458,029
+588
+0.1% +$18.3K 0.05% 435
2026
Q1 		$11.4M Buy
+457,441
New +$8.27M 0.04% 478
2022
Q4 		– Sell
-7,395
Closed -$410K – 840
2022
Q3 		$410K Hold
7,395
– – 0.01% 606
2022
Q2 		$385K Buy
7,395
+3,517
+91% +$196K 0.01% 587
2022
Q1 		$319K Buy
+3,878
New +$369K 0.01% 531
2021
Q4 		– Sell
-21,951
Closed -$4.15M – 781
2021
Q3 		$4.15M Hold
21,951
– – 0.07% 283
2021
Q2 		$4.08M Buy
21,951
+354
+2% +$69.3K 0.08% 242
2021
Q1 		$4.92M Buy
21,597
+3,379
+19% +$802K 0.11% 197
2020
Q4 		$3.96M Buy
+18,218
New +$3.02M 0.1% 169

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Woodline Partners's STRO Position: Q2 2026 in Review

Woodline Partners increased its Sutro Biopharma (STRO) stake by 0.13% in Q2 2026, buying an estimated $18.3K and bringing the position to 458,029 shares worth $15.2M. The position accounts for 0.05% of the portfolio, ranked #435.

Woodline Partners first reported a position in STRO in Q4 2020 and has held it in 9 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Woodline Partners held 458,029 shares of Sutro Biopharma worth $15.2M as of Q2 2026.
  • Woodline Partners bought 588 Sutro Biopharma shares in Q2 2026, an estimated $18.3K.
  • Sutro Biopharma made up 0.05% of Woodline Partners's portfolio in Q2 2026, its #435 holding.
  • Woodline Partners first reported a position in Sutro Biopharma in Q4 2020 and has held it in 9 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.